Office of Biomedical Advanced Research and Development Authority Broad Agency Announcement (BAA)

The overall objective of this contract is to develop multiplexed SARS-CoV-2 antigen panel assay kits for human antibody (e.g., IgA and IgG when appropriate) quantification by electrochemiluminescence in serum and mucosal samples. The antigen panel assay kits shall be capable of measuring total antibodies that block binding of angiotensin-converting enzyme 2 (ACE2) to the receptor binding domain (RBD) of the SARS-CoV-2 ancestor and selected variants printed in custom configurations. The antigen panels shall be capable of measuring Ig, IgG and IgA antibodies that bind to the whole Spike (S), receptor binding domain (RBD) and nucleocapsid (N) antigens of the SARS-CoV-2 ancestor and selected variants printed in custom configurations. The antigen panel assay kits shall include appropriate standards and controls to support development and validation of the assays described
above at USG-designated laboratories.
The scope of work includes providing multiplexed SARS-CoV-2 antigen panels assay kits for human antibody (e.g., IgA and IgG as appropriate), to be used in either direct SARS-CoV-2 antigen-binding or ACE2 receptor-blocking, quantification by electrochemiluminescence. The Contractor will function as a USG antigen panel assay kit development and ISO 9001 manufacturer to support advanced research and development and evaluation of COVID-19 vaccines. Data from these panels may be used in primary, secondary, and exploratory immunogenicity endpoint analyses for vaccine clinical studies as
well as monitoring their subsequent efficacy.